Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma

被引:38
|
作者
Li, X [1 ]
Ye, DF [1 ]
Xie, X [1 ]
Chen, HZ [1 ]
Lu, WG [1 ]
机构
[1] Zhejiang Univ, Sch Med, Womens Hosp, Hangzhou 310006, Peoples R China
关键词
ovarian carcinoma; immunosuppression; CD4(+)CD25(+) regulatory T cell;
D O I
10.1081/CNV-200067142
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To study the frequency of the CD4(+)CD25(+) regulatory T cells (Tregs) in the patients with ovarian carcinoma and its possible mechanism. Methods. The percentages of CD4(+)CD25(+) Tregs in the peripheral blood lymphocytes (PBLs), tumor infiltrating lymphocytes (TILs) and tumor associated lymphocytes (TALs) from 13 patients with ovarian carcinoma and in the PBLs from 14 healthy women were determined by flow cytometry. The expression of CD69 on CD4(+)PBLs from the patients was detected. PBLs from healthy women were cultured in complete RPMI 1640 containing the supernatant from SKOV3 cell line with or without PHA (phytohemagglutinin) stimulation for 72 hours, then the percentage of CD4(+)CD25(+) T cells was detected. Results. CD4(+)CD25(+) Tregs in the PBLs from patients with ovarian carcinoma were significantly increased compared with those from the control. The percentage of CD4(+)CD25(+) Tregs in TILs was higher than that in PBLs and TALs from the patients, but not significantly. The expression of CD69 on CD4(+)PBLs from the patients was negative. The percentages of CD4(+)CD25(+) T cells in PBLs cultured with SKOV3 supernatant elevated significantly compared with those without supernatant whether PHA was added or not (P=0.001 and 0.001, respectively). Conclusion. There is an increasing of the proportion of CD4(+)CD25(+) Tregs in PBLs, TILs and TALs of the patients with ovarian carcinoma, which probably results from up-regulation of soluble factor secreted by ovarian carcinoma cells.
引用
收藏
页码:399 / 403
页数:5
相关论文
共 50 条
  • [31] Interleukin-2 is essential for CD4+CD25+ regulatory T cell function
    de la Rosa, M
    Rutz, S
    Dorninger, H
    Scheffold, A
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (09) : 2480 - 2488
  • [32] Influence of CD4+CD25+ regulatory T cells on the transendothelial migration of CD4+CD25- T cells
    Bedke, T.
    Kretz, M.
    Mahnke, K.
    Enk, A. H.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 46 - 46
  • [33] Alteration in circulating Cd4+cd25+ regulatory T cell numbers and function in atherosclerosis
    Mor, A
    Luboshits, G
    Planer, D
    Keren, G
    George, J
    CIRCULATION, 2005, 112 (17) : U74 - U74
  • [34] LAT-mediated signaling in CD4+CD25+ regulatory T cell development
    Koonpaew, S
    Shen, SD
    Flowers, L
    Zhang, WG
    JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (01): : 119 - 129
  • [35] Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses
    Kursar, M
    Bonhagen, K
    Fensterle, J
    Köhler, A
    Hurwitz, R
    Kamradt, T
    Kaufmann, SHE
    Mittrücker, HW
    JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12): : 1585 - 1592
  • [36] CD4+CD25+ T Regulatory Cells in Transplantation Tolerance: 25 Years On
    Hall, Bruce M.
    TRANSPLANTATION, 2016, 100 (12) : 2533 - 2547
  • [37] Paralysis of CD4+CD25+ regulatory T cell response in chronic autoimmune encephalomyelitis
    Matsumoto, Yoh
    Sakuma, Hiroshi
    Kohyama, Kuniko
    Nakajima, Mie
    Park, Il-Kwon
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 151 - 152
  • [38] Role of TCR specificity in CD4+CD25+ regulatory T-cell selection
    Picca, Cristina Cozzo
    Larkin, Joseph, III
    Boesteanu, Alina
    Lerman, Melissa A.
    Rankin, Andrew L.
    Caton, Andrew J.
    IMMUNOLOGICAL REVIEWS, 2006, 212 : 74 - 85
  • [39] Paralysis of CD4+CD25+ regulatory T cell response in chronic autoimmune encephalomyelitis
    Matsumoto, Yoh
    Sakuma, Hiroshi
    Kohyama, Kumko
    Park, Il-Kwon
    JOURNAL OF NEUROIMMUNOLOGY, 2007, 187 (1-2) : 44 - 54
  • [40] Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
    Audia, S.
    Nicolas, A.
    Cathelin, D.
    Larmonier, N.
    Ferrand, C.
    Foucher, P.
    Fanton, A.
    Bergoin, E.
    Maynadie, M.
    Arnould, L.
    Bateman, A.
    Lorcerie, B.
    Solary, E.
    Chauffert, B.
    Bonnotte, B.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03): : 523 - 530